Study on the of Anagrelide on Platelet Factor 4 and Vascular Endothelial Growth Factor Levels in Patients with Essential Thrombocythemia

The myeloproliferative neoplasm Essential Thrombocythemia (ET) is characterised by a high platelet count and platelet activation connected to angiogenesis. Platelet activation is promoted by vascular endothelial growth factor (VEGF), and active platelets emit VEGF, according to research. Anagrelide (ANA) is a new medication that lowers platelet counts and inhibits platelet activation.

Platelet count, platelet factor 4 (PF4) levels, as an indicator of platelet activation, and corrected platelet VEGF (VEGFPLT), as an indicator of angiogenesis-related platelet activation, were investigated in ET patients treated with hydroxyurea (HU) and interferon (IFN) or ANA in combination with antiaggregants. Prior to treatment, all patients had higher platelets, PF4, and VEGFPLT levels than controls. All patients had lower platelets after therapy, although PF4 and VEGFPLT were higher in the HU and IFN- groups compared to controls, and normal in the ANA group. There was no association between PF4 and platelets, however PF4 and VEGFPLT had a positive correlation.

If the findings are verified in larger research, ANA may have anti-platelet and anti-angiogenic characteristics.

Author(S) Details

Rossella R. Cacciola
Institute of Hematology, University of Catania, Catania, Italy.

Ernesto Di Francesco
Institute of Hematology, University of Catania, Catania, Italy.

Rosario Giustolisi
Institute of Hematology, University of Catania, Catania, Italy.

Emma Cacciola
Institute of Hematology, University of Catania, Catania, Italy.

View Book:- https://stm.bookpi.org/RDMMR-V4/article/view/4184

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *